Becton Dickinson/Clontech Laboratories
This article was originally published in The Gray Sheet
Executive Summary
BD expects to complete its acquisition of molecular biology research products maker Clontech by Aug. 31. Under a revision of their April 28 merger agreement (1"The Gray Sheet" May 3, p. 13), the deal will now be for $200 mil. in cash instead of stock
You may also be interested in...
Becton's $200 Mil. Clontech Buy Broadens Life Science Research Offerings
Becton Dickinson's $200 mil. acquisition of molecular biology research products maker Clontech Labs will significantly broaden the BD Biosciences life science research product line, according to the company.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.